Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

30 Mar 2019

Abstract excerpt

Immune checkpoint inhibitor (ICI) activates host's anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induce tumor regression in a subset of advanced cancer patients. In clinical practice, a main concerning for choosing ICI is the low response rate. Even though multiple predictive biomarkers such as PD-L1 expression,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Cancer Immunotherapy and Biomarkers
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30925919
DOI: 10.1186/s12943-019-0974-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatmentPMID 30925919Read ↗

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, other than Abscopal Effect: A Systematic ReviewSemantic proximity Read ↗

Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsSemantic proximity Read ↗

Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.Semantic proximity Read ↗

Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy.Semantic proximity Read ↗

Programmed cell death‐1 blockade therapy in melanoma: Resistance mechanisms and combination strategiesSemantic proximity Read ↗

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancerSemantic proximity Read ↗

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.Semantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.Semantic proximity Read ↗

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignanciesSemantic proximity Read ↗

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity.Semantic proximity Read ↗

Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.